Stefan Vestring, Alexandra Dorner, Jonas Scholliers, Konstantin Ehrenberger, Andrea Kiss, Luis Arenz, Alice Theiss, Paul Rossner, Sibylle Frase, Catherine Du Vinage, Elisabeth Wendler, Tsvetan Serchov, Katharina Domschke, Josef Bischofberger, Claus Normann
The partial N-methyl-D-aspartate receptor (NMDAR) agonist D-Cycloserine (DCS) has been evaluated for the treatment of a wide variety of psychiatric disorders, including dementia, schizophrenia, depression and for the augmentation of exposure-based psychotherapy. Most if not all of the potential psychiatric applications of DCS target an enhancement or restitution of cognitive functions, learning and memory. Their molecular correlate is long-term synaptic plasticity; and many forms of synaptic plasticity depend on the activation of NMDA receptors...
January 9, 2024: Translational Psychiatry